Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Taiho to Promote Aloxi with 800 MRs
February 15, 2010
- FUJIFILM to Embark on Generic Business
February 15, 2010
- IHI, UMN Pharma to Create Joint Venture for Flu Vaccines
February 15, 2010
- Fuji Pharma, Mochida to Jointly Develop G-CSF Biosimilar
February 15, 2010
- QOL, Growell, Medipal to Operate Pharmacies for Elderly Consumers
February 15, 2010
- BioNumerik Initiates Global PIII for Tavocept
February 15, 2010
- Toho, Itochu to Create Joint Venture in China with Local Drug Wholesaler
February 15, 2010
- AnGes Completes Enrollment in PIII Trial for Allovectin-7
February 15, 2010
- Mepact Now Available for Osteosarcoma in the EU: Takeda
February 15, 2010
- SEMINAR
February 15, 2010
- ASKA to Comarket Minclea with Nihon Pharm.
February 15, 2010
- Abbott Aims at Top Share in DES Market in Japan with XIENCE V
February 15, 2010
- Kyowa Kirin to Jointly Distribute KW-2246 with Hisamitsu
February 15, 2010
- RDKK to Launch K-RAS Gene Mutation Test Kit in April
February 15, 2010
- Wakunaga to Build New Plant in California
February 15, 2010
- Nipro to Acquire Home Diagnostics of the US
February 15, 2010
- Generics Priced Higher Than Original Drugs Should Not Be Regarded as Generics: Korosho
February 15, 2010
- HSTTC Mediates Transfer of NCC-Developed Technology to MKI
February 15, 2010
- Only 2% of Current Non-Users to Start Prescribing Rasilez: SSRI
February 15, 2010
- Panel to Review Drugs, Indications That Need Development
February 15, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…